Evidence map›Paper›PMID 41886220›Full record

ArticleTargeted oncology2026

Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics.

Natalia A Quijano Cardé, Jin Niu, Yue Guo, Jia Zhou, Xiao Qiu, Yaming Su, Carlos Pérez-Ruixo, Deeksha Vishwamitra, Caroline Hodin, Tara Stephenson and 9 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03145181 phase1active not recruitingnot on this map

64007957MMY1001: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

TypeinterventionalSponsorJanssen Research & Development, LLCRan2017 to 2027Enrolled302ConditionsHematological MalignanciesArmsTeclistamab (IV), Teclistamab(SC)
NCT04557098 phase2active not recruitingnot on this map

TECLIMMY1001-P3: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

TypeinterventionalSponsorJanssen Research & Development, LLCRan2020 to 2027Enrolled194ConditionsHematological MalignanciesArmsTeclistamab
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Natalia A Quijano CardéJohnson & Johnson, Spring House, PA, USA. nquijano@its.jnj.com.ORCID http://orcid.org/0000-0001-9379-6658
Jin NiuJohnson & Johnson, Spring House, PA, USA.
Yue GuoJohnson & Johnson, Spring House, PA, USA.
Jia ZhouJohnson & Johnson, Spring House, PA, USA.
Xiao QiuJohnson & Johnson, Spring House, PA, USA.
Yaming SuJohnson & Johnson, Raritan, NJ, USA.
Carlos Pérez-RuixoJohnson & Johnson, Madrid, Spain.
Deeksha VishwamitraJohnson & Johnson, Spring House, PA, USA.
Caroline HodinJohnson & Johnson, Beerse, Antwerp, Belgium.
Tara StephensonJohnson & Johnson, Spring House, PA, USA.
Athena ZuppaJohnson & Johnson, Spring House, PA, USA.
Katherine ChastainJohnson & Johnson, Raritan, NJ, USA.
Rachel KobosJohnson & Johnson, Raritan, NJ, USA.
Mahesh N SamtaniJohnson & Johnson, Raritan, NJ, USA.
Weirong WangJohnson & Johnson, Spring House, PA, USA.
Nahor Haddish-BerhaneJohnson & Johnson, Spring House, PA, USA.
Niels W C J Van de DonkAmsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Alfred L GarfallAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jeffrey V MatousColorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, CO, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTeclistamab is a B cell maturation antigen × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma. Two step-up doses (SUDs) are used to mitigate the risk of cytokine release syndrome (CRS). For patients who experience dose delays, it is uncertain what length of delay necessitates repeat SUDs.

objectiveWe used modeling simulations and retrospective analysis of the phase 1/2 MajesTEC-1 study to optimize recommendations for repeat SUDs after teclistamab dose delay. PATIENTS AND

methodsPopulation pharmacokinetic modeling was used to simulate teclistamab serum concentrations after dose delays to assess the duration required to achieve levels comparable to estimated trough concentrations (C

resultsMedian teclistamab serum concentrations were estimated to drop to levels comparable to the simulated SUD 2 median C

conclusionsThese analyses suggest teclistamab can be safely restarted without repeat SUD for delays ≤ 62 days, and at SUD 2 for delays 63-111 days. For delays > 111 days, both SUDs should be administered as instructed per label before resuming treatment at 1.5 mg/kg. CLINICAL

trial registrationNCT03145181 (phase 1, May 9, 2017); NCT04557098 (phase 2, September 21, 2020).

Indexed as

Antibodies, BispecificCytokinesMultiple MyelomaClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicFemaleHumansMaleRetrospective StudiesAntibodies, BispecificCytokines

Identifiers

PMID41886220
PMCPMC13222323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.